Cytosorbents (CTSO) Tops Q3 EPS by 1c, Misses on Revenue

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. LITE
4. ABBV
5. AAPL
6. MRVL
7. CL
8. TFII
9. LYB
10. RXRX

Go back to Cytosorbents (CTSO) Tops Q3 EPS by 1c, Misses on Revenue

CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update

November 13, 2025 4:05 PM EST

Third quarter 2025 revenue of $9.5 million, up 10% year-over-year Amended credit agreement with Avenue Capital Group which strengthens our balance sheet with an additional $2.5 million of cash, and extends the interest only-period through December 31, 2026, with an additional $2.5 million available and an additional extension of the interest-only period to June 30, 2027 with DrugSorb-ATR FDA marketing approval Implemented Workforce and Cost Reduction Program to accelerate path to cash-flow breakeven to Q1 2026 Submitted DrugSorb-ATR De Novo pre-submission package to FDA, with meeting expected in... More